Navigation Links
Karmanos Researchers Report Enhanced Chemosensitivity of Pancreatic Cancer Cells by Black Seed Component
Date:4/13/2008

SAN DIEGO, April 13 /PRNewswire-USNewswire/ -- The Barbara Ann Karmanos Cancer Institute researchers today presented, at the American Association for Cancer Research annual meeting in San Diego, CA, the potential benefits of Thymoquinone (TQ), a compound present in the oil of black seeds (Nigella sativa), in treating pancreatic cancer.

(Logo: http://www.newscom.com/cgi-bin/prnh/20071106/KARMANOSCANCERINSTITUTELOGO )

For centuries, these black seeds have been consumed in Asia, Africa and the Middle East to promote health and fight disease. TQ, an active component of the seeds, has been isolated for its promise as a chemopreventative agent. Pancreatic cancer cells currently have a high degree of inherent and acquired chemoresistance to standard chemotherapy agents Gemcitabine and/or Oxaliplatin, making these drugs only moderately effective.

"Our goal with this study was to increase the effectiveness of current pancreatic cancer treatments with a naturally occurring substance," said Sanjeev Banerjee, Ph.D., researcher, working under the leadership of Fazlul Sarkar, Ph.D., professor of pathology at the Karmanos Cancer Institute, Wayne State University. "We also explored the molecular mechanisms associated with TQ to promote better therapeutic outcomes."

Drs. Banerjee and Sarkar, along with Karmanos researchers Ramzi Mohammad, Ph.D. and Zhiwei Wang, Ph.D., pre-treated pancreatic tumor cells possessing different molecular signatures (HPAC, BxPC-3, Panc-1 and MDA Panc-28, COLO 357, L3.6pl), with TQ prior to administering Gemcitabine and Oxaliplatin. They found that TQ significantly enhanced the chemosensitivity of the tumor cells, making the Gemcitabine and Oxaliplatin agents more effective in treating the cancer. The TQ pre-treatment improved the drugs' effect on promoting cancer cell death and halting tumor cell growth.


'/>"/>

SOURCE Karmanos Cancer Institute
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. McCarty Cancer Foundation Awards $50,000 Grant for Myeloma Research Program at Karmanos Cancer Institute
2. Nominations for Outstanding Cancer Survivor Award Being Accepted by Karmanos Cancer Institute Through April 27
3. Kroger Pink Tag Campaign Raises $137,500 for Breast Cancer Research and Awareness at Karmanos Cancer Institute
4. Danialle Karmanos Work It Out Launches Dynamic Blog
5. Karmanos Cancer Center Most Preferred Hospital for Cancer Care According to 2007 Survey
6. Susan G. Komen For The Cure, Karmanos Cancer Institute, Local Hospitals Call on Policymakers to Address Injustice and Unfairness in Breast Cancer Incidence and Mortality
7. Susan G. Komen for the Cure, Karmanos Cancer Institute, Community Leaders, Breast Cancer Survivors and Activists to Gather at Forum and Call for Action on Breast Cancer
8. Penn researchers find targeted therapy combination overcomes treatment resistance in liver cancer
9. Researchers find disparities in depression among older Hispanics in US
10. Researchers Identify New Genetic Links to Psoriasis
11. Penn researchers discover modus operandi of heart muscle protein
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/4/2009)... say, health and fitness need not suffer, , ...eople are cutting back in these tough economic tim... can you cut back when it comes to your health? ,...re smart about it. There are ways to save money, t...sically fit and receiving needed medical care. ,...
(Date:7/3/2009)... recognise service excellence during National Cust... London (PRWeb UK) July 3, 2009 -- Compa... urged to celebrate the importance of excellent cu... Service Week - 5-11 October., , ,Employers in all...shop and local authority see the week, which is or...
(Date:7/3/2009)...t-resistant strain, study finds , , ...sistant tuberculosis might someday meet its match ..., suggests a new study. , Researchers, led by...go, report in the July 3 issue of PLoS Computatio...e and tolcapone have the potential to treat the di...
(Date:7/3/2009)... hazards , , FRIDAY, July 3 (HealthDay N...ost 10,000 injuries every year in the United State...u and others safe while enjoying the key summer ho.... Corporation, which runs several Georgia-based me... safety: , Obey all local laws regarding firewor...
Breaking Medicine News(10 mins):Health News:Living Healthily on Less 2Health News:Living Healthily on Less 3Health News:Living Healthily on Less 4Health News:Businesses Urged to Sign Up and Celebrate Customer Service 2Health News:New Weapons in Fight Against TB? 2Health News:Put Safety First on the 4th 2
...on has developed a chemical process for building ...’s response to drugs or screen patients for thousa...e simple lab test. The DNA chip is similar to a co...cules instead of electronic circuitry. It is desig...
...s can cause harmful side effect when combined with...upplements reduced// blood levels of the saquinavi...tors that are effective at slowing the progression...lements, blood concentrations of saquinavir decrea...
...lood fats called triglycerides to an increased ris...ans to pay closer attention to triglyceride levels... blood triglycerides and treatments to modify this...ce the stroke burdens. Doctors have learned that ...
...a federal judge to hold the American Red Cross in ...n its blood collection program. FDA is acting toda...iously its role as guardian of the safety of the n...al to the public health. // Despite a promise mad...
Other Medicine News:Health News:DNA biochip for genetic screening 2
(Date:6/28/2009)...ICHMOND, Calif., June 29 ... announced that a key research milestone has been ...h Genentech, Inc., a wholly-owned member of the Ro...ovel characteristics for pharmaceutical protein pr... finger DNA-binding protein nuclease (ZFN) technol...
(Date:6/26/2009)...RIDGEWATER, N.J., June 26 /PRNewswire-FirstCall/ -...) has just been made aware of data associated with...ies. The results of these data clearly show that n...possible causal relationship between Lantus(R) (in...rence of malignancies, as the authors of the study...
(Date:6/25/2009)... Thirteen Renowned Medical Experts Slated to Atten..., June 25 The first national sympo...rgy drinks will be held next week in New York City...rch and analysis from their respective fields. Th...ion and research on the health impacts that the $5...
(Date:6/25/2009)...CUROX(R) and EMBEDA (TM) Data Highlighted at the C...ng , , RENO, Nev., June 25 Ki...nced that the Company is presenting safety and eff..., two novel opioid analgesic formulations that are... College on Problems of Drug Dependence. King is ...
Breaking Medicine Technology:Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech 2Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech 3Sanofi-aventis Stands Behind the Safety of Lantus(R) 2Sanofi-aventis Stands Behind the Safety of Lantus(R) 3SUNY Youth Sports Institute Convenes Top Experts in NYC Next Week to Present Research & Analysis on Energy Drink Health Impacts 2SUNY Youth Sports Institute Convenes Top Experts in NYC Next Week to Present Research & Analysis on Energy Drink Health Impacts 3SUNY Youth Sports Institute Convenes Top Experts in NYC Next Week to Present Research & Analysis on Energy Drink Health Impacts 4King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use 2King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use 3King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use 4King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use 5King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use 62008 Pew Fellowship in Marine Conservation awarded to Dr Marie Jo 26 23235 3Blle Rochet from IFREMER 2126 12008 Pew Fellowship in Marine Conservation awarded to Dr Marie Jo 26 23235 3Blle Rochet from IFREMER 2126 22008 Pew Fellowship in Marine Conservation awarded to Dr Marie Jo 26 23235 3Blle Rochet from IFREMER 2126 32008 Pew Fellowship in Marine Conservation awarded to Dr Marie Jo 26 23235 3Blle Rochet from IFREMER 2126 4Sonic Innovations Announces Results for Fourth Quarter and Full Year 2007 11086 1Sonic Innovations Announces Results for Fourth Quarter and Full Year 2007 11086 2Sonic Innovations Announces Results for Fourth Quarter and Full Year 2007 11086 3Sonic Innovations Announces Results for Fourth Quarter and Full Year 2007 11086 4Sonic Innovations Announces Results for Fourth Quarter and Full Year 2007 11086 5Sonic Innovations Announces Results for Fourth Quarter and Full Year 2007 11086 6Sonic Innovations Announces Results for Fourth Quarter and Full Year 2007 11086 7AtriCure Announces Web Cast and Conference Call of Fourth Quarter and Full Year 2007 Financial Results 11084 1AtriCure Announces Web Cast and Conference Call of Fourth Quarter and Full Year 2007 Financial Results 11084 2The Advisory Board Company Reports Fiscal Year 2008 Third Quarter Results 11082 1The Advisory Board Company Reports Fiscal Year 2008 Third Quarter Results 11082 2The Advisory Board Company Reports Fiscal Year 2008 Third Quarter Results 11082 3The Advisory Board Company Reports Fiscal Year 2008 Third Quarter Results 11082 4The Advisory Board Company Reports Fiscal Year 2008 Third Quarter Results 11082 5The Advisory Board Company Reports Fiscal Year 2008 Third Quarter Results 11082 6The Advisory Board Company Reports Fiscal Year 2008 Third Quarter Results 11082 7The Advisory Board Company Reports Fiscal Year 2008 Third Quarter Results 11082 8The Advisory Board Company Reports Fiscal Year 2008 Third Quarter Results 11082 9The Advisory Board Company Reports Fiscal Year 2008 Third Quarter Results 11082 10The Advisory Board Company Reports Fiscal Year 2008 Third Quarter Results 11082 11The Advisory Board Company Reports Fiscal Year 2008 Third Quarter Results 11082 12The Advisory Board Company Reports Fiscal Year 2008 Third Quarter Results 11082 13The Advisory Board Company Reports Fiscal Year 2008 Third Quarter Results 11082 14The Advisory Board Company Reports Fiscal Year 2008 Third Quarter Results 11082 15
...ALT LAKE CITY, UT, June 11, 2007 (MARKET WIRE via ...DAQ: MYGN) (<a target=,"_blank" href="http://www.m...it presented a mathematical comparison of a,"Stagg... trial,design with a "Natural History Staggered St...ciation Prevention Conference held,June 9 - 12, 20...
...LTHAM, Mass.--(BUSINESS WIRE)--Jun 12, 2007 - Resu...Pharmaceuticals, (Nasdaq:,OSCI) FACTIVE(R) (gemifl...t of community-acquired pneumonia of mild to moder... issue of the,peer-reviewed Journal of Antimicrobi...-line. The data from the Phase III clinical,trial ...
Other Medicine Technology:Myriad Genetics Presents Mathematical Comparison of Disease,Modification Trial Designs at Alzheimer's ConferenceCurrent,Flurizan Phase 3 Study Design May Demonstrate Disease Modification 2Myriad Genetics Presents Mathematical Comparison of Disease,Modification Trial Designs at Alzheimer's ConferenceCurrent,Flurizan Phase 3 Study Design May Demonstrate Disease Modification 3Myriad Genetics Presents Mathematical Comparison of Disease,Modification Trial Designs at Alzheimer's ConferenceCurrent,Flurizan Phase 3 Study Design May Demonstrate Disease Modification 4Myriad Genetics Presents Mathematical Comparison of Disease,Modification Trial Designs at Alzheimer's ConferenceCurrent,Flurizan Phase 3 Study Design May Demonstrate Disease Modification 5July Issue of Journal of Antimicrobial Chemotherapy Highlights,Study of Factive Tablets for Five-Day Treatment of,Community-Acquired Pneumonia 2July Issue of Journal of Antimicrobial Chemotherapy Highlights,Study of Factive Tablets for Five-Day Treatment of,Community-Acquired Pneumonia 3July Issue of Journal of Antimicrobial Chemotherapy Highlights,Study of Factive Tablets for Five-Day Treatment of,Community-Acquired Pneumonia 4July Issue of Journal of Antimicrobial Chemotherapy Highlights,Study of Factive Tablets for Five-Day Treatment of,Community-Acquired Pneumonia 5
Inquire
The Cypress quick test is a rapid immunochromatographic screening test for the detection of antibodies to Trypanosoma cruzi. It can be used with whole blood, serum or plasma. The method employs a un
Sprint Quattro Secure™ is a Steroid-Eluting, True Bipolar, Active Fixation ICD Lead.
The Medtronic Subcutaneous Lead System Model 6996 SQ is implanted subcutaneously with the use of the Medtronic Tunneling Tool Model 6996T. Improved SQ design and implant technique offer low DFTs, a f
Medicine Products: